Provided by Tiger Trade Technology Pte. Ltd.

ResMed

231.52
+3.081.35%
Post-market: 231.520.00000.00%19:30 EDT
Volume:1.73M
Turnover:399.65M
Market Cap:33.40B
PE:22.20
High:234.14
Open:229.44
Low:228.54
Close:228.44
52wk High:293.81
52wk Low:180.27
Shares:144.25M
Float Shares:143.49M
Volume Ratio:1.34
T/O Rate:1.20%
Dividend:2.40
Dividend Rate:1.04%
EPS(TTM):10.43
EPS(LYR):10.43
ROE:24.27%
ROA:14.00%
PB:5.07
PE(LYR):22.20

Loading ...

ResMed Is Maintained at Overweight by Keybanc

Dow Jones
·
Jun 22

KeyBanc Adjusts Price Target on ResMed to $266 From $290, Maintains Overweight Rating

MT Newswires Live
·
Jun 22

ResMed price target lowered to $266 from $290 at KeyBanc

TIPRANKS
·
Jun 22

ResMed Inc. Stock Rises Thursday, Outperforms Market

Dow Jones
·
Jun 19

ResMed Loses Bull as Margin Outlook Moderates -- Market Talk

Dow Jones
·
Jun 18

ResMed Inc. Stock Falls Wednesday, Underperforms Market

Dow Jones
·
Jun 18

ResMed Shares Fall After Morgan Stanley Downgrade

MT Newswires Live
·
Jun 18

ResMed Cut to Equal-Weight From Overweight by Morgan Stanley

Dow Jones
·
Jun 17

Resmed Shares Down 1.2% Premarket After Morgan Stanley Cuts to Equal Weight From Overweight

THOMSON REUTERS
·
Jun 17

Morgan Stanley Downgrades ResMed to Equalweight From Overweight, Adjusts PT to $230 From $286

MT Newswires Live
·
Jun 17

ResMed Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
Jun 16

ResMed Is Maintained at Buy by Citigroup

Dow Jones
·
Jun 16

Citigroup Adjusts Price Target on ResMed to $270 From $340, Maintains Buy Rating

MT Newswires Live
·
Jun 15

He's 87 and Has Never Taken a RMD From His 401(k). Here's His Secret. -- Barrons.com

Dow Jones
·
Jun 13

ResMed Inc. Stock Rises Friday, Outperforms Market

Dow Jones
·
Jun 13

ResMed study links PAP therapy to 23% lower cardiovascular ER visit, hospitalization risk in OSA patients with hypertension

Reuters
·
Jun 11

Resmed Inc-Statement of Changes in Beneficial Ownership

THOMSON REUTERS
·
Jun 10

Statement of changes in beneficial ownership-RMD.N

Reuters
·
Jun 10

ResMed Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
Jun 10

ResMed CEO Michael J. Farrell sells 4,991 common shares worth $967,658.34

Reuters
·
Jun 10